I-HoME for Caregiver Burden
Trial Summary
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment I-HoME for reducing caregiver burden?
The In-Home care coordination program showed promise in reducing avoidable hospitalizations, which could indirectly lessen caregiver burden by managing health issues at home. Additionally, a mental health home visit service partnership improved caregiver satisfaction and reduced their burden, suggesting that similar home-based interventions like I-HoME might be effective.12345
Is I-HoME safe for caregivers?
Research on hospital-in-the-home care, which is similar to I-HoME, shows that there can be negative and unexpected events, but these studies help identify safety indicators to improve care. While specific safety data for I-HoME isn't available, understanding these risks can help ensure safer care environments.46789
How does the I-HoME treatment differ from other treatments for caregiver burden?
The I-HoME treatment is unique because it focuses on providing more and better information, personal counseling, and increased support during evenings, nights, and weekends, which are times when caregivers often feel the most burdened. This approach addresses the emotional and informational needs of caregivers, which are not typically the focus of other treatments.1011121314
What is the purpose of this trial?
The purpose of this study is to pilot test the adapted Improving Home hospice Management of End-of-life issues through technology (I-HoME) intervention with family caregivers of patients with advanced Alzheimer's Disease and related dementia. Data will be collected regarding intervention feasibility and acceptability.
Research Team
Veerawat Phongtankuel, MD
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for family caregivers of patients with advanced Alzheimer's Disease and related dementias. It aims to support them in managing end-of-life issues using a technology-based intervention called I-HoME.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive video visits with a nurse practitioner for up to six visits every 2 weeks to address symptom management and care needs
Follow-up
Participants are monitored for changes in caregiver anxiety, burden, perception of patient's pain, and behavioral symptoms of dementia
Treatment Details
Interventions
- I-HoME
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
National Institute on Aging (NIA)
Collaborator